Wegovy maker Novo Nordisk's board slims down
Digest more
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...
The company is 'evolving beyond its strong heritage in diabetes care' and is looking to 'revolutionise obesity care,' she ...
The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...
Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback